I take a drug that when I first started using it it was in phase 3 trial. They had not worked out the dosage so I was on a huge dose daily. One of the side effects was appetite suppression. It was not like the GLP-1 drugs in that other side effects were minimal. I lost 2 stone in 3 months, my family thought I had an eating disorder. Fortunately when the trial finished the dose was adjusted and I stopped losing weight.
The drug is also used for Parkinson’s, unfortunately because the dosage is 40x that used for my condition, twenty years after it was introduced they discovered that is caused heart valve damage in Parkinson’s patients. As a precaution I have regular echocardiograms even though I’m low risk.
Had they followed the same pattern as the WLI and utilised the side effects of appetite suppression, developing a weight loss drug, they would be facing massive legal action. The drug has few side effects, the appetite suppression did not affect the digestive system, I just never felt hungry. It didn’t affect my energy levels if anything it was a bit of a stimulant.
It took a long time for serious complications to surface. And to those who claim the WLI have been around long enough to be tried and tested, Mounjaro is of the same family of drugs but has additional modes of action. It’s only been around for 2-3 yrs. Despite being in the same families you will always get the odd one or two drugs that cause serious side effects both short term and longterm despite the safety of other proven members of the family.
I took a drug that was in the same class/family as Tamoxifen, after 3 mnths it caused acute liver failure. Not long after my reaction was reported it was withdrawn from the market because it was found to cause liver failure in over 30% of patients who were prescribed it. It had been on the market for a while before it became apparent that the risk of liver failure was high because of its niche use.
All drugs can cause serious side effects but the risk varies. A 1 in a million risk is not likely to cause concern but a 1 in 10 would probably lead to withdrawal if the drug.
There are serious risks associated with WLI but when used for diabetes and obesity the risk of death or serious side effect as a result of the disease far outweighs the risk from the drug. In a healthy patient who has no risk from associated disease, the risk of serious side effects becomes a much greater problem.
If you develop gallstones from the associated rapid weight loss then you have effectively greatly increased the risk of death through infection or as a result of surgery. If you didn’t need to lose weight you increased your risk unnecessarily.